- Главная
- Разное
- Дизайн
- Бизнес и предпринимательство
- Аналитика
- Образование
- Развлечения
- Красота и здоровье
- Финансы
- Государство
- Путешествия
- Спорт
- Недвижимость
- Армия
- Графика
- Культурология
- Еда и кулинария
- Лингвистика
- Английский язык
- Астрономия
- Алгебра
- Биология
- География
- Детские презентации
- Информатика
- История
- Литература
- Маркетинг
- Математика
- Медицина
- Менеджмент
- Музыка
- МХК
- Немецкий язык
- ОБЖ
- Обществознание
- Окружающий мир
- Педагогика
- Русский язык
- Технология
- Физика
- Философия
- Химия
- Шаблоны, картинки для презентаций
- Экология
- Экономика
- Юриспруденция
Why Juno Therapeutics Jumped 12% In September презентация
Содержание
- 1. Why Juno Therapeutics Jumped 12% In September
- 2. What: This clinical-stage biotech company is researching
- 3. Juno Therapeutics
- 4. So What: Reengineering immune system’s T-cells. Using
- 5. So what continued…
- 6. So what continued… JCAR 015: 87% complete
- 7. Now what: JCAR 015: Phase 2 pivotal
- 8. Now what continued: Needs to confirm prior
- 9. The next billion-dollar iSecret. The
Слайд 2What:
This clinical-stage biotech company is researching T-cell cancer therapies.
JCAR 015 for
lymphoma & leukemia.
Various others in early stage trials for leukemia & lymphoma.
Shares jumped 12.1% in September.
Presented at Morgan Stanley’s Global Healthcare Conference on September 16.
Various others in early stage trials for leukemia & lymphoma.
Shares jumped 12.1% in September.
Presented at Morgan Stanley’s Global Healthcare Conference on September 16.
Слайд 4So What:
Reengineering immune system’s T-cells.
Using chimeric antigen receptor (CAR) approach to
allow T-cells to bind to and kill cancer cells.
Potential FDA filing in late 2016/early 2017.
10 drug candidates in human trials by 1H2016.
Collaborating with Celgene.
Potential FDA filing in late 2016/early 2017.
10 drug candidates in human trials by 1H2016.
Collaborating with Celgene.
Слайд 6So what continued…
JCAR 015:
87% complete response/remission rate in relapsing/recurring adult acute
lymphoblastic leukemia.
JCAR 017:
91% complete response/remission rate in relapsing/recurring pediatric acute lymphoblastic leukemia.
JCAR 017:
91% complete response/remission rate in relapsing/recurring pediatric acute lymphoblastic leukemia.
Слайд 7Now what:
JCAR 015:
Phase 2 pivotal trial ongoing.
Began in Q3 2015.
Scheduled to
complete in 2017.
Слайд 8Now what continued:
Needs to confirm prior findings.
Watch safety data.
Focus on rates
of cytokine response syndrome.
23% rate in prior studies.
Remember, this is a clinical stage company without revenue and without products on the market.
Suitable only for the most risk tolerant of investors.
23% rate in prior studies.
Remember, this is a clinical stage company without revenue and without products on the market.
Suitable only for the most risk tolerant of investors.
Слайд 9
The next billion-dollar iSecret.
The Apple Watch was locked away deep
within Apple's famous design lab, and the company did everything in its power to keep its game changer a secret. But the secret is out, and best of all, our analysts have discovered a "roundabout way" to invest in the gadget... for just a fraction the price of AAPL stock....To see our free report on these stocks, just click here now.
